AP Gruppe
Probe 1 *) Probe 2
7 LITERATURVERZEICHNIS
Alpert J. S., Thygesen K., Antman E., Bassand J. P. (2000)
Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology / American College of Cardiology Comittee for the redefinition of myocardial infarction. J. Am Coll Cardiol 2000; 36:959-69.
Anagnostou A., Liu Z., Steiner M., Chin K., Lee E. S., Kessimian N., Noguchi C. T. (1994)
Erythropoietin receptor mRNA expression in human endothelial cells. Proc.
Natl. Acad. Sci. USA, 1994, Vol. 1: 3974-3978.
Andersen H. R., Nielsen T. T., Rasmussen K et al. (2003)
The Danish multicenter randomised trial on thrombolytic therapy versus acute coronary angioplasty in acute myocardial infarction. N Engl J Med 2003;
8:349-56.
Asahara, T., Takahashi, T., Kalka, C. et al. (1998)
A novel function for VEGF: mobilisation of bone marrow-derived endothelial progenitor cells. Circulation 1998; 98: I-605.
Bonnefoy E., Lapostolle F., Leizorovicz A., Steg G., McFadden E. P., Dubien P. Y., Cattan S., Boulenger E., Machecourt J. (2002)
Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study, CAPTIM study group. Lancet 2002; 360:825-29.
Brown K. J., Maynes S. F., Bezos A., Maguire D. J., Ford M. D., Parish C. R.
(1996)
A novel in vitro assay for human angiogenesis. Lab. Invest. 1996, 75: 539-555.
Calvillo L., Latini R., Kajstura J., Annarosa L., Anversa P., Ghezzi P., Salio M., Cerami A., Brines M. (2003)
Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl. Acad. Sci.
USA 2003; 100: 4802-4806.
Campeau L. (1976)
Letter: grading of angina pectoris. Circulation 1976; 54:522-23.
Carlini R. G., Reyes A. A., Rothstein M. (1995)
Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Intern, 1995, 740-745.
Chong Z. Z., Kang J. Q., Maiese K. (2002)
Angiogenesis and plasticity: role of erythropoietin in vascular system. J.
Hemother. Stem Cell Res. 2002; 11: 863-71.
Clark S. C., Kamen R. (1987)
The human haematopoetic colony-stimulating factors. Science 1987; 236:
1229-1237.
Cotes P. M. (1989)
Physiological studies of erythropoietin in plasma. Erythropoietin, Springer Verlag 1989; 57-79.
Depping R., Kawakami K., Ocker H., Wagner J. M., Henninglake M., Noetzold A., Sievers H. H., Wagner K. F. (2005)
Expression of the erythropoietin receptor in human heart. J. Throc. Cardiov.
Sur. 2005; 130: 877-878.
Digicaylioglu M., Bichet S., Marti H. H., Wenger R. H., Rivas L. A., Bauer C., Gassmann M. (1995)
Localisation of specific erythropoietin binding sites in defined areas of the mouse brain. Proc. Natl. Acad. Sci. USA 1995; 92 3717-3720.
Dorbal M. S., Wang F. F., Goldwasser E. (1985)
The role of carbohydrate in erythropoietin action. Endocrinol. 1985; 116: 2293-2299.
Egrie J. C., Goldwasser E. (1992)
Erythropoietin. Human Cytokines – Handbook for Basic and Clinical Research, Blackwell Scientific Publications, Boston 1992; 383-98.
Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., Rustenbeck H. H., Breiter N., Jacob S., Knerlich F., Bohn M., Poser W., Ruther E., Kochen M., Gefeller O., Gleiter C., Wessel T. C., De Ryck M., Itri L., Prange H., Cerami A., Brines M., Siren A. L. (2002)
Mol. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol.
Med. 2002; 8: 495-505.
Fadok V. A., Voelker D. R., Campbell P. A., Cohen J. J., Bratton D. L., Henson P. M. (1992)
Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992;
148:2207-16.
Ferrario, M., Massa, M., Rosti, V., Campanelli, R., Ferlini, M., Marinoni, B., De Ferrari, G. M., Meli, V., De Amici, M., Repetto, A., Verri, A., Bramucci, E., Tavazzi, L. (2007)
Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. European Heart Journal 2007; 28, 1805-1813.
18. Freemantle N., Cleland J., Young P., Mason J., Harrison J. (1999) Beta blockade after myocardial infarction: systematic review and meta-regression-analysis. BMJ 1999; 318:1730-37.
Gibbons R. J., Holmes D. R., Reeder C. S., Bailey K. R., Hopfenspringer M.
R., Gersh B. J. (1993)
Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993; 328:685-91.
Gorio A., Gokmen N., Erbayraktat S., Yilmaz O., Madaschi L., Cichetti C., Di Giulio A. M., Vardar E., Cerami A., Brines M. (2002)
Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc. Natl. Acad. Sci. USA 2002; 99:9450-9455.
Grimm C., Wenzel A., Groszer M., Mayser H., Seeliger M., Samardzija M., Bauer C., Gassmann M., Reme C. E. (2002)
HIF-1 induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat. Med. 2002; 8: 718-724.
Grines C. L., Patel A., Zijlstra F. et al. (2003)
Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomised trails. Am Heart J 2003; 145:47-57.
Gruppo Italiano per lo Studio della Sopravvivenza nell`infarto Miocardico, GISSI-3. (1994)
Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction.
Lancet 1994; 343:1115-22.
Hamm C. W., Arntz H. R., Bode C et al. (2004)
Leitlinien Akutes Koronarsyndrom Teil 1: Akutes Koronarsyndrom ohne ST-Hebung. Z. Kardiol. 2004; 93:72-90. Leitlinien: Akutes Koronarsyndrom Teil 2:
Akutes Koronarsyndrom mit ST-Hebung. Z Kardiol 2004; 93:330.
Hamm C. W., Braunwald E. (2000)
A classification of unstable angina revisited. Circulation 2000; 102:118.
Hamm C. W., Voigtländer T., Meyer J. (2007)
Akuter Myokardinfarkt. Rationelle Diagnostik und Therapie in der Inneren Medizin 2007; 8D: 3.
Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., Mildner-Rihm C., Martin H., Zeiher A. M., Dimmeler S. (2003)
Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilisation. Blood 2003; 102(4): 1340-1346.
Herold G. und Mitarbeiter. (2000) Innere Medizin 2000, 196-197.
ISIS-4. (1995)
Collaborative Group ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345:669-85.
Jaquet K., Krause K., Tawakol-Khodai M., Geidel S., Kuck K.-H. (2002) Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc. Res.
2002; 64: 326-33.
Jelkmann W., Wiedemann G. (1990)
Serum erythropoietin level. Relationships to blood hemoglobin concentration and erythrocytic activity of the bone marrow. Klin. Wschr. 1990; 68: 403-407.
Jelkmann W., Wolff M., Fandrey J. (1990)
Modulation of the production of erythropoietin by cytokines: in vitro studies and their clinical implications. Contrib Nephrol 1990; 87: 68-77.
Juul S. E. (2000)
Nonerythropoietic roles of erythropoietin in the fetus and neonate. Neonat.
Haematol. 2000; 27: 527-41.
Juul S. E., Yachnis A. T., Christensen R. D. (1998)
Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum. Dev. 1998; 52: 235-249.
Kalka C., Takahashi T., Masuda H., Asahara T., Isner J. M. (1999)
VEGF: Therapeutische Angiogenese und Vaskulogenese in der Behandlung kardiovaskulärer Erkrankungen. Med Klin 1999, 94: 193-201.
Kawakami M., Sekiguchi M., Sato K., Kozaki S., Takahashi M. (2001)
Erythropoietin receptor-mediated inhibition of exocytic glutamate release confers neuroprotection during chemical ishemia. J. Biol. Chem. 2001; 276:
39469-39475.
Keeley E. C., Boura J. A., Grines C. L. (2003)
Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361:13-20.
Kerr J. F. R., Wyllie A. H., Currie A. R. (1972)
A basic biological phenomenon with wideranging implication in tissue kinetics.
Br J Cancer 1972; 26: 239-57.
Korbling M., Estrov Z. (2003)
Adult stem cells for tissue repair – a new therapeutic concept? N Engl J Med 2003; 349: 570-82.
Kranz A., Mayr U., Frank H., Waltenberg J. (1999)
The coronary endothelium: a target for vascular endothelial growth factor.
Human coronary artery endothelial cells express functional receptors for VEGF in vitro and in vivo. Lab Invest, 1999, 79: 985-991.
Kranz A., Rau C., Kochs M., Waltenberger J. (2000)
Elevation of vascular endothelial growth factor-A, serum levels following acute myocardial infarction. Evidence for its origin and functional significance. J.
Mol. Cell Cardiol., 2000; 32: 65-72.
Krause K., Jaquet K., Geidel S., Schneider C., Mandel C., Schiele W., Nauertz M., Stoll H.-P., Schmeller M.-L., Lass M., Ostermeyer J., Kuck K.-H. (2006)
Percutaneous endocardial injection of erythropoietin: Assessment of cardioprotection by electromechanical mapping. Europ J Heart Fail 2006;
8:443-450.
Kroll J., Waltenberger J. (2000)
Regulation der Endothelfunktion und der Angiogenese durch den Vaskulären Endothelialen Wachstumfaktor-A. Z. Kardiol 2000, 89: 206-218.
Lai P. H., Everett R., Wang F. F. et al. (1986)
Structural characterisation of human erythropoietin. J. Biol. Chem. 1986; 261:
3116-3121.
Lazarous D. F., Shou M., Scheinowitz M., Hodge E., Thirumurti V., Kitsiou A. N., Stiber J.A., Lobo A.D., Hunsberger S., Guetta E., Epstein S.E., Unger E.F. (1996)
Comparative effects of basic fibroblast growth factor (FGF) and vascular endothelial factor (VEGF) on coronary collateral development and the arterial response to injury. Circulation 1996, 94: 1074-1082.
Levy A. P., Levy N. S., Loscalzo J., Calderone A., Takahashi N., Yeo K. T., Koren G, Colucci W. S., Goldberg M. A. (1995)
Regulation of vascular endothelial growth factor in cardiac myocytes. Circ Res, 1995, 76: 758-766.
Lin F.-K., Suggs S., Lin C.-H. et al. (1985)
Cloning of the human erythropoietin gene. Proc. Natl. Acad. Sci. USA 1985;
82: 7580-7584.
Maiese K., Li F., Chong Z. Z. (2005)
New avenues of exploration for erythropoietin. Jama 2005; 293: 90-95.
Majno G., Joris I. (1995)
Apoptosis, oncosis and necrosis. An Overview of cell death. Am J Pathol 1995; 146:3-15.
Marti H. H., Wenger R. H. Rivas L. A., Straumann U., Digicaylioglu M., Henn V., Yonekawa Y., Bauer C., Gassmann M. (1996)
Erythropoietin gene expression in human, monkey and murine brain. Eur. J.
Neurosci. 1996; 8: 666-676.
Masuda S., Okano M., Yamagishi K., Nagao M., Ueda M., Sasaki R. (1994) A novel site of erythropoietin production. J. Biol. Chem. 1994; 269: 19488-19493.
Meyer J., Rupprecht H. J. (2007)
Koronare Herzkrankheit. Rationelle Diagnostik und Therapie in der Innere Medizin 2007; 7D:5.
Miller M. E., Chandra M., Garcia J. F. (1985)
Clinical application of measurement of serum immunoreactive levels of erythropoietin. Ann. NY Acad. Sci. 1985; 459: 375-381.
Miyake T., Kung C. K. H., Goldwasser E. (1977)
Purification of human erythropoietin. J Biol Chem 1977; 252:5558-64.
Moon C., Krawczyk M., Ahn D., Ahmet I., Paik D., Lakatta E. G., Talan M. I.
(2003)
Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc. Natl. Acad. Sci. USA 2003;
100: 11612-11617.
Mörl H., Haders P., Von Fallois J. (1998)
Koronare Herzkrankheit. Walter de Gruyter Verlag, Berlin, New York 1998:1-2.
Nielsen OJ, Thaysen JH. (1989)
Response to erythropoietin in anaemic haemodialysis patients. J Intern Med 1989; 226: 89-94.
Oberhammer F., Wilson J. W., Dive C., Morris I. D., Hickmann J. A., Wakeling A. F., Walker P. R., Sikorska M. (1993)
Apoptotic death in epithelial cells: cleavage of DANN to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 1993; 12: 3679-84.
Parsa C. J., Matsumoto A., Kim J., Riel R. U., Pascal L.S., Walton G.B., Thompson R. B., Petrofski J. A., Annex B. H., Stamler J. S., Koch W. J.
(2003)
A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest.
2003; 112: 999-1007.
Peters H. D., Fandrey J. (1997)
ERYPO, Erythropoietin human, rekombiniert. Janssen-Cilag, 3. Auflage, 1997;
23.
Pfisterer M., Cox J. L., Granger C. B. et al. (1998)
Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1998; 32:634-40.
Quaini F., Urbanek K., Beltrami A. P., Finato N., Beltrami C. A., Nadal-Ginard B, Kajstura J., Leri A., Anversa P. (2002)
Chimerism of the Transplanted Heart. N Engl J Med 2002; 346:5-15.
Ribatti D., Presta P, Vacca A., Ria R., Guiliani R. et al. (1999)
Human erythropoietin induces a proangiogenic phenotype in cultured endothelial cells and stimulates neovascularisation in vivo.Blood 1999: 2627-2636.
Schächinger V., Assmus B., Zeiher A. M. (2004)
Stammzelltherapie bei ischämischer Herzkrankheit. Klinikarzt 2004; 33: 68-73.
Sengupta S., Gherardi E., Sellers L. A., Wood J. M., Sasisekharan R., Fan T-P D. (2003)
Hepatocyte growth factor (HGF)/ scatter factor can induce angiogenesis independently of VEGF. Art., Thomb. and Vasc. Biol. 2003, 23:69.
Siren A. L., Knerlich F., Poser W., Gleiter C. H., Bruck W., Ehrenreich H.
(2001)
Erythropoietin and erythropoietin receptor in human ishemic/hypoxic brain.
Acta Neuropathol. 2001; 101: 271-6.
Stack G., Gorski J. (1984)
Endocrinology 1984; 115: 1141-1150.
Statistisches Bundesamt. (2003)
Todesursachenstatistik 2003; Deutsches Ärzteblatt, Heft 20, 2006, A 1378.
Stierle U., Niederstadt C. (1999)
Klinikleitfaden Kardiologie 1999, 200-208, 246- 253.
Stroud R. M., Wells J. A. (2004)
Mechanistic diversity of cytokine receptor signaling across cell membranes.
Sci. STKE 2004; 2004: re. 7.
Tramontano A. F., Muniyappa R., Black A. D., Blendea M. C., Cohen I., Deng L., Sowers J. R., Cutaia M. V., El-Sherif N. (2003)
Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem. Biophys. Res. Commun. 2003;
308: 990-994.
Vanags D. M., Porn-Ares M. I., Coppola S., Burgess D. H., Orrenius S.(1996)
Protease involment in fodrin cleavage and phosphatidylserine exposure in apoptosis. J Biol Chem 1996; 271:31075-85.
Wagner K. F., Katschinski K. M., Hasegawa J., Schumacher D., Meller B., Gembruch U., Schramm U., Jelkmann W., Gassmann M., Fandrey J.
(2001)
Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood 2001; 97: 536-542.
Walker P. R., Kokileva L., Le Blanc J., Sikorska M. (1993)
Detection of the initial stages of DNA-fragmentation in apoptosis.
Biotechniques 1993; 15: 1032-40.
Wang G. L., Jiang B. H., Rue E. A., Semenza G. L. (1995)
Hypoxia-inducible-factor-1(HIF 1) is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 1995; 92: 5510-5514.
Watkins P.C., Eddy R., Hoffman H. et al. (1986)
Regional assignment of the erythropoietin gene to human chromosome region 7qter-q22. Cytogent Cell Genet. 1986; 42: 214-218.
Wenger R.H. (2002)
Cellular adaptation to hypoxia: O2-sensing protein hydroxylases. Hypoxia-inducible transcription factors, and O2-regulated gene expression. FASB J.
2002 16: 1151-1162.
Westphal G., Niederberger E., Blum C., Wollman Y., Knoch T. A., Rebel W., Debus J., Friedrich E. (2002)
Erythropoietin and G-CSF receptors in human tumor cells: expressions and aspects regarding functionality. Tumori. 2002;88:150-9.
Wide L., Bengtsson C., Birkegard G. (1989)
Circadian rhythm of erythropoietin in human serum. Br. J. Hematol. 1989; 72:
85-90.
Wyllie A. H. (1980)
Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284: 555-6.
Yasuda Y., Masuda S., Chikuma M., Inoue K., Nagao M., Sasaki R. (1998) Estrogen-dependent production of erythropoietin in uterus and its implications in uterine angiogenesis. J. Biol. Chem. 1998, Vol. 273: 25381-25387.